Table 3.
Summary of probiotic intervention studies for the treatment of eczema.
| Probiotic used | Treatment period | Major outcomes | Study |
|---|---|---|---|
| B. breve M-16V | 4 weeks (N = 15 infants) | Improved allergic symptoms | Hattori et al. (2003) |
| Increased Bifidobacterium numbers | |||
| B. lactis Bb12 or LGG | 8 weeks (N = 27 infants) | Improvement in skin condition | Isolauri et al. (2000) |
| LGG 5 × 108 CFU/g | 4 weeks (N = 27 infants) | Improved clinical score | Majamaa and Isolauri (1997) |
| L. fermentum VRI-033 PCC 1 × 109 CFU | 16 weeks (N = 56 infants) | Reduced SCORAD | Weston et al. (2005) |
| Improved skin condition | |||
| L. rhamnosus or LGG 3 × 108 CFU/g | 12 weeks (N = 50 infants) | No effect on SCORAD | Brouwer et al. (2006) |
| LGG 10 × 109 CFU | 8 weeks (N = 54 infants) | No difference in clinical symptoms, immunological parameters, and quality of life | Folster-Holst et al. (2006) |
| LGG 5 × 109 CFU | 12 weeks (N = 54 infants) | No difference in symptoms, IgE levels | Gruber et al. (2007) |
| L. rhamnosus 19070-2 and L. reuteri DSM122460 1 × 1010 CFU | 6 weeks (N = 43 children) | Improved clinical symptoms | Rosenfeldt et al. (2003) |
| LGG (5 × 109 CFU) or MIX (LGG, 5 × 109 CFU; L. rhamnosus LC705, 5 × 109 CFU; B. breve Bbi99, 2 × 108 CFU; and P. freudenreichii ssp. shermanii JS, 2 × 109 CFU) | 4 weeks (N = 230 children) | Improved clinical symptoms in LGG group | Viljanen et al. (2005a) |
| L. sakei 5 × 109 CFU | 12 weeks (N = 75 children) | Decreased SCORAD, improved clinical effects | Woo et al. (2010) |
| B. bifidum, L. acidophilus, L. casei, and L. salivarius 2 × 109 CFU | 8 weeks (N = 40 children) | Reduced SCORAD, total IgE | Yesilova et al. (2012) |
| B. breve M-16V and a GOS/FOS mixture | 12 weeks (N = 90 infants) | No difference in SCORAD | van der Aa et al. (2010) |
| 1.3 × 109 CFU/100 ml | Modulated intestinal microbiota | ||
| L. salivarius and prebiotic or prebiotic alone 2 × 109 CFU | 8 weeks (N = 60 children) | Reduced SCORAD, improved clinical condition, less medication use | Wu et al. (2012) |
| L. casei 1 × 108 CFU/ml | 12 months (N = 187 children) | No difference in asthma symptoms, lower incidence of rhinitis | Giovannini et al. (2007) |
| L. gasseri A5 2 × 109 CFU/capsule | 8 weeks (N = 105 children) | Decreased clinical symptoms, reduced allergic cytokines | Chen et al. (2010) |